+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

BRCA1 and BRCA2 mutations and the risk for colorectal cancer

BRCA1 and BRCA2 mutations and the risk for colorectal cancer

Clinical Genetics 87(5): 411-418

Women who carry a BRCA1 or BRCA2 mutation are at high risk of breast and ovarian cancer, and may be at moderately increased risk of other cancer types. This review examines studies to date that have evaluated the risk of BRCA1 and BRCA2 mutations for colorectal cancer. Accurate knowledge of colorectal cancer risk in BRCA1/2 carriers is important, because colonoscopy screening can prevent colorectal cancer through the removal of adenomatous polyps. Most studies that have identified an increased risk for colorectal cancer in BRCA1/2 mutation carriers were in high-risk cancer families, while studies that found no association were conducted in specific populations and involved the analysis of founder mutations. A recent prospective study of 7015 women with a BRCA1 or BRCA2 mutation identified significant fivefold increased risk of colorectal cancer among BRCA1 mutation carriers younger than 50 years [standardized incidence ratio (SIR): 4.8; 95% CI: 2.2-9], but not in women with a BRCA2 mutation or in older women. Based on this evidence, women with BRCA1 mutations should be counseled about their increased risk for early-onset colorectal cancer, and offered colonoscopy at 3- to 5-year intervals between the ages of 40 and 50 years, and should follow population guidelines thereafter.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 051744330

Download citation: RISBibTeXText

PMID: 25195694

DOI: 10.1111/cge.12497

Related references

BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. Journal of the National Cancer Institute 96(1): 15-21, 2004

Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes & Development 11(10): 1226-1241, 1997

Response: Re: Brca1 and Brca2 Founder Mutations and the Risk of Colorectal Cancer. Jnci Journal of the National Cancer Institute 96(15): 1185-1186, 2004

BRCA1 and BRCA2 founder mutations are not associated with a high risk of colorectal cancer. American Journal of Human Genetics 69(4 Suppl.): 253, 2001

BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. Journal of the National Cancer Institute 110(11): 1178-1189, 2018

BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. International Journal of Cancer 140(9): 2051-2059, 2017

High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families. Human Genetics 102(5): 549-556, 1998

Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. Breast Cancer Research and Treatment 107(3): 431-441, 2007

BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. Journal of Clinical Oncology 17(10): 3017-3024, 1999

BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Letters 245(1-2): 90-95, 2006

Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers. Breast Cancer Research and Treatment 116(1): 195-200, 2008

Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study. Anticancer Research 20(1b): 559-561, 2000

Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. Journal of the National Cancer Institute 96(1): 68-70, 2004

Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status. Breast Cancer Research and Treatment 127(3): 819-829, 2011

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Research 13(1): R20, 2014